INS and type 2 diabetes mellitus: The data presented here suggest that both liraglutide 1.8 mg and 1.2 mg added to basal insulin, as well as IDegLira, are clinically effective and cost-effective treatment options, compared with lixisenatide 20 μg added to basal insulin, for patients with T2D uncontrolled on basal insulin in Sweden.